Journal of Antimicrobial Chemotherapy · 2023 · 11 citations · 17 references
PharmacyPharmacologyPharmacotherapyAntimicrobial PharmacotherapyClinical PharmacologyMedical MicrobiologyCombination Antimicrobial TherapyDe-escalation Of Antimicrobial TherapyEmpiric Antimicrobial TherapyIntravenous-to-oral Switch TherapyUrinary Tract Infection PharmacotherapyAntibiotic Step-down TherapyAntimicrobial Resistance In Urinary Tract InfectionsEscherichia ColiFosfomycin TherapyLogistic RegressionMicrobiological CurePost Hoc AnalysisUrinary Tract Infection Antibiotic Therapy
BACKGROUND: Fosfomycin is a potentially attractive option as step-down therapy for bacteraemic urinary tract infections (BUTI), but available data are scarce. Our objective was to compare the effectiveness and safety of fosfomycin trometamol and other oral drugs as step-down therapy in patients with BUTI due to MDR Escherichia coli (MDR-Ec). METHODS: Participants in the FOREST trial (comparing IV fosfomycin with ceftriaxone or meropenem for BUTI caused by MDR-Ec in 22 Spanish hospitals from June 2014 to December 2018) who were stepped-down to oral fosfomycin (3 g q48h) or other drugs were included. The primary endpoint was clinical and microbiological cure (CMC) 5-7 days after finalization of treatment. A multivariate analysis was performed using logistic regression to estimate the association of oral step-down with fosfomycin with CMC adjusted for confounders. RESULTS: Overall, 61 patients switched to oral fosfomycin trometamol and 47 to other drugs (cefuroxime axetil, 28; amoxicillin/clavulanic acid and trimethoprim/sulfamethoxazole, 7 each; ciprofloxacin, 5) were included. CMC was reached by 48/61 patients (78.7%) treated with fosfomycin trometamol and 38/47 (80.9%) with other drugs (difference, -2.2; 95% CI: -17.5 to 13.1; P = 0.38). Subgroup analyses provided similar results. Relapses occurred in 9/61 (15.0%) and 2/47 (4.3%) of patients, respectively (P = 0.03). The adjusted OR for CMC was 1.11 (95% CI: 0.42-3.29, P = 0.75). No relevant differences in adverse events were seen. CONCLUSIONS: Fosfomycin trometamol might be a reasonable option as step-down therapy in patients with BUTI due to MDR-Ec but the higher rate of relapses would need further assessment.
17
Dafna Yahav, Erica Franceschini, Fidi Koppel et al. · Clinical Infectious Diseases · 2018 · 412 citations · Full text
Pranita D. Tamma, Anna Conley, Sara E. Cosgrove et al. · JAMA Internal Medicine · 2019 · 153 citations · Full text
José Molina, Enrique Montero-Mateos, Julia Praena‐Segovia et al. · Clinical Microbiology and Infection · 2021 · 136 citations
Kalpana Gupta, Thomas M. Hooton, Kurt G. Naber et al. · Clinical Infectious Diseases · 2011 · 114 citations · Full text